HC Wainwright Issues Positive Outlook for Chimerix Earnings

Chimerix, Inc. (NASDAQ:CMRX) – Investment analysts at HC Wainwright lifted their Q4 2024 earnings estimates for shares of Chimerix in a research note issued to investors on Wednesday, December 11th. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will earn ($0.24) per share for the quarter, up from their prior forecast of ($0.25). HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Chimerix’s Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($0.99) EPS.

Other equities analysts also recently issued reports about the stock. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st. Wedbush reiterated an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research report on Tuesday, December 10th.

Chimerix Trading Up 0.3 %

Chimerix stock opened at $2.95 on Friday. The company has a fifty day simple moving average of $1.07 and a 200 day simple moving average of $0.96. The company has a market cap of $265.32 million, a P/E ratio of -3.14 and a beta of 1.02. Chimerix has a 1-year low of $0.75 and a 1-year high of $3.39.

Institutional Investors Weigh In On Chimerix

A number of institutional investors have recently made changes to their positions in the stock. Valeo Financial Advisors LLC raised its position in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 69,505 shares in the last quarter. Marshall Wace LLP bought a new stake in Chimerix in the second quarter valued at $137,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 138,098 shares during the period. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.